STEM CELLS

Cover image for Vol. 33 Issue 5

Edited By: Jan A. Nolta

Impact Factor: 7.133

ISI Journal Citation Reports © Ranking: 2013: 2/18 (CELL & TISSUE ENGINEERING); 4/68 (Hematology); 11/165 (Biotechnology & Applied Microbiology); 16/203 (Oncology); 33/185 (Cell Biology)

Online ISSN: 1549-4918

Press Releases


Embargo Policy

Materials submitted to STEM CELLS are embargoed for release until 12:01 a.m. Eastern Standard Time the day of online publication or until 2 p.m. EST on the day before the mailing date (for the print edition), whichever comes first. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until one week before online posting of the article or one week before the mailing date, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.

Communication Among Scientists or Clinical Investigators

STEM CELLS does not wish to hinder communication among scientists or clinical investigators. Authors are permitted to discuss their manuscripts with their peers and to present their work to their peers at professional conferences. However, authors should not discuss or distribute any portion of an unpublished manuscript in a manner that may intentionally or inadvertently lead to the distribution of the material to the media or general public. Manuscript material may be projected onto a screen for viewing, but no handouts or photocopies of article proofs or preprints may be disseminated. Furthermore, we ask that comments to the media do not elaborate upon the content of your presentation. Finally, please inform STEM CELLS that you are planning to make such a presentation.

Reprogramming Stem Cells to a More Basic Form Results in More Effective Transplant, Study Shows

Durham, NC November 2011 -- Chinese stem cell scientists have published new research that improves the survival and effectiveness of transplanted stem cells. The research led by Dr Hsiao Chang Chan, from the Chinese University of Hong Kong, is published in STEM CELLS.

Research into differentiation has led to a variety of breakthroughs as stem cell researchers harvest cells from one part of the body and genetically adapt them to fulfill a specialized role. However, if the implanted cells are too much like the cells of the targeted area they may not have the plasticity to engraft and repair the injured tissue.

“Stem cell differentiation and transplantation has been shown to improve function in conditions including degenerative diseases and blood supply disorders,” said Dr Chan. “However, the survival rate of transplanted cells in patients limits their overall effectiveness, which is a barrier to clinical use.”

To overcome this issue Dr Chan’s team explored de-differentiation, a process that reverts specialized, differentiated cells back to a more primitive cell.
The team focused their research on multipotent stem cells, (MSCs) which can be altered into a variety of cell types through differentiation. Bone marrow MSCs have the potential to differentiate into each of the three basic types of lineage cells which form bone (osteocytes), cartilage (chondrocytes) and fat tissue (adipocytes).

The team first differentiated bone marrow MSCs towards a neuronal lineage, but then removed the differentiation conditions, allowing the cell to revert back to a form with more basic cellular characteristics.

Following this process the team recorded increased cell survival rates following transplants. In an animal model de-differentiated cells were found to be more effective in improving cognitive functions and in aiding recovery from strokes, compared to un-manipulated stem cells both in living specimens and in laboratory experiments.

The results confirm that de-differentiation is a workable technique for reengineering cells to an earlier, more primitive state, but with increased cell survival rates which increase their potential for clinical use.

“The finding that MSCs can be reprogrammed to have enhanced survival and therapeutic efficacy in an animal model with potential application to patients is extremely exciting as it may provide a novel and clinically practical method to overcome low cell survival in cell-based therapy,” concluded Dr Chan. “We are currently exploring other beneficial properties of the reprogrammed MSCs for other therapeutic applications.”

“Many investigators have speculated that differentiation should improve the utility of stem cells for transplantation, but how far to differentiate the cells for the best outcome is a difficult question. Dr Chan’s team have helped provide an answer by educating mesenchymal stem cells by pre-differentiating to the desired lineage before de-differentiation, making MSCs easier to manipulate and implant,” said Dr. Mark Pittenger, STEM CELLS Associate Editor.

“Interesting questions still remain for future work such as which factors are expressed in the pre-differentiated stem cells that persist upon de-differentiation and can the de-differentiated cells be frozen for future use?”

-------------------------------------------------------------------------------------------------------------------------------------
This study is published in STEM CELLS. Media wishing to receive a PDF of this article may contact Lifesciencenews@wiley.com
Full citation:

Liu, Yang; Jiang, Xiaohua; Zhang, Xiaohu; Chen, Rui; Sun, Tingting; Fok, Kin Lam; Dong, Jianda; Tsang, Lai Ling; Yi, Shaoqiong; Ruan, Yechun; Guo, Jinghui; Yu, Mei Kuen; Tian, Yue; Chung, Yiu Wa; Yang, Mo; Xu, Wenming; Chung, Chin Man; Li, Tingyu; Chan, Hsiao, “Dedifferentiation-reprogrammed mesenchymal stem cells with improved therapeutic potential”, STEM CELLS, Wiley, November 2011, DOI: 10.1002/stem.764

Paper URL: http://doi.wiley.com/10.1002/stem.764

Contact the Author:
Dr. Chan can be contacted via Ms. Amy Tsu
Communication Office
Chinese University of Hong Kong
amytsui@cuhk.edu.hk

About the Journal:
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research.

For more information, please visit: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1549-4918

STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press:
Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA and Belfast, United Kingdom publishes two internationally renowned peer-reviewed journals: STEM CELLS®, now in its 29th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, is in its 16th year and is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. Both journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. In January 2012, AlphaMed Press will launch a new peer-reviewed journal, STEM CELLS Translational Medicine that will hasten the clinical applications of stem cell therapies.

About Wiley
Wiley is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley publishes nearly 1,500 peer-reviewed journals and 1,500 new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world’s most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.

New Evidence for Spinal Membrane as a Source of Stem Cells May Advance Treatment of Spinal Cord Injuries

Durham, NC October 2011 – Italian and Spanish scientists studying the use of stem cells for treating spinal cord injuries have provided the first evidence to show that meninges, the membrane which envelops the central nervous system, is a potential source of self-renewing stem cells. The research, published in STEM CELLS, develops the understanding of cell activation in central nervous system injuries; advancing research into new treatments for spinal injuries and degenerative brain disorders.

The team focused their research on spinal cord injuries, caused when the spinal cord is damaged by trauma rather than disease. Depending on the severity a spinal injury can lead from pain to full paralysis, with high social and medical care costs. As the spinal cord lacks the ability to regenerate, the potential for patient recovery is severely limited.

“Our research offers the first evidence that the spinal cord meninges, the system of membranes which cover the surface of the brain and the spinal cord, contains stem cells which are capable of self-renewal and proliferation,” said lead authors Dr Ilaria Decimo and Dr Francesco Bifari, at the University of Verona.

Following a spinal injury meningeal cells increase in number and migrate to form glial scars and the team believe this process explains part of the mechanism of stem cell activation in central nervous system diseases; a mechanism which could in turn be used for treatments.

Dr Decimo’s team microdissected samples of spinal cord meninges from adult rats revealing that meningeal cells contain crucial stem cell properties. It is these properties which increase following a spinal cord injury.

"Our research emphasizes the role of meninges cells in the reaction to spinal cord trauma and indicates for the first time that spinal cord meninges harbour stem cells which are activated by injury," concluded Dr, Decimo. “Further testing could result in a strategic turnaround for advancing regenerative medicine for treating neurological disorders and spinal cord injuries.”

“This study underlines the importance of endogenous stem cells,” said STEM CELLS Editor Dr Miodrag Stojkovic. “Identification of these cells is crucial for understanding the basic mechanisms of cell biology and tissue repair, but also to identify drugs and chemicals which might be used to mobilize meningeal stem cells.”

-------------------------------------------------------------------------------------------------------------------------------------
This paper is published in STEM CELLS. Media Wishing to request a copy should contact Lifesciencenews@wiley.com or phone 44 (0)1243 770 375

Full Citation:
Decimo. I, Bifari. F, Rodriguez. F, Malpeli. G, Dolci. S, Lavarini. V, Pretto. S, Vasquez. S, Sciancalepore. M, Montalbano. A, Berton. V, Krampera. M, Fumagalli. G, “Nestin- and DCX-positive cells reside in adult spinal cord meninges and participate to injury-induced parenchymal reaction,” STEM CELLS, Wiley, October 2011, DOI: 10.1002/stem.766

Paper URL: http://doi.wiley.com/10.1002/stem.766

Contact the Author:
Dr Decimo can be contacted via
Sara Mauroner
University of Verona’s
sara.mauroner@univr.it
(0039) 0480281715

About STEM CELLS: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research.

For more information, please visit: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1549-4918

STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA and Belfast, United Kingdom publishes two internationally renowned peer-reviewed journals: STEM CELLS®, now in its 29th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, is in its 16th year and is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. Both journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. In January 2012, AlphaMed Press will launch a new peer-reviewed journal, STEM CELLS Translational Medicine that will hasten the clinical applications of stem cell therapies.

About Wiley
Wiley is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley publishes nearly 1,500 peer-reviewed journals and 1,500 new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world’s most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities
 

 

SEARCH

SEARCH BY CITATION